You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | n/a | 3.9% |
| Div Cover | n/a | 2.2 |
| Op Mrgn | n/a | 23.3% |
| ROCE | n/a |
| Latest | Forecast | |
|---|---|---|
| P/E | n/a | 11.3 |
| PEG | n/a | 1.2 |
| Price / Revenue | n/a | 2.0 |
| Price / Book value | n/a |
| Latest | Forecast | |
|---|---|---|
| Revenue | 0.0% | -17.4% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 12.6% |
| DPS | 0.0% | 0.2% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | 30,186.00 | 3,525.00 | 111.80p | 11.8 | 1.3 | 9% | 80.00p | 6.0% |
| 2018-12-31 | 30,821.00 | 4,800.00 | 119.40p | 12.5 | 1.8 | 7% | 80.00p | 5.4% |
| 2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 14.4 | 3.8 | 4% | 80.00p | 4.5% |
| 2020-12-31 | 34,099.00 | 6,968.00 | 1.17p | 11.6 | -1.8 | -6% | 0.81p | 6.0% |
| 2021-12-31 | 34,114.00 | 5,442.00 | 113.20p | 14.2 | -6.1 | -2% | 80.00p | 5.0% |
| GSK to 'vigorously defend' Zantac claims; Haleon says not a party to claims Sharecast News | 12 Aug |
|---|---|
| GSK, Haleon, Sanofi slump amid Zantac litigation woes Sharecast News | 11 Aug |
| GSK lifts full-year outlook as Q2 sales rise Sharecast News | 27 Jul |
| Statement: Zantac (ranitidine) litigation | 12-Aug-22 07:00 |
|---|---|
| Director/PDMR Shareholding | 11-Aug-22 11:53 |
| Director/PDMR Shareholding | 10-Aug-22 16:59 |
| Total Voting Rights | 01-Aug-22 18:13 |
| Director/PDMR Shareholding | 01-Aug-22 13:45 |